Two stocks in Healthcare
Convatec Group vs Hikma Pharmaceuticals: profit, growth, debt and price compared
Hikma Pharmaceuticals is stronger on 4 of 7 figures: profit margin, debt, price for its expected profit and dividend. Convatec Group is stronger on 2: sales growth and price trend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Convatec GroupCTEC.L | Hikma PharmaceuticalsHIK.L | |
|---|---|---|
| Net margin | 5.0% | Stronger: 11.3% |
| Revenue growth, past year | Stronger: +4.40% | +4.20% |
| Debt to equity | 121.8% | Stronger: 77.1% |
| Forward P/E | 15.7× | Stronger: 9.2× |
| Dividend yield | 2.25% | Stronger: 3.84% |
| Analysts | Strong buy · 19 | Strong buy · 12 |
| From its 200-day average | Stronger: +17.9% | +5.8% |
Share price over the past year
- Convatec Group+15.1%
- Hikma Pharmaceuticals+7.7%
20 Nov 202518 Nov 2026
Convatec Group or Hikma Pharmaceuticals: which is stronger?
- HIK.L
Which is more profitable?
Hikma Pharmaceuticals keeps more of each sale as profit: 11.3% against 5.0%.
- CTEC.L
Which is growing its sales faster?
Convatec Group is growing its sales faster: +4.40% over the past year, against +4.20%.
- HIK.L
Which has borrowed less?
Hikma Pharmaceuticals has borrowed less: its debt is 77.1% of what its shareholders own, against 121.8% for Convatec Group.
- HIK.L
Which costs less for the profit it is expected to make?
Hikma Pharmaceuticals costs less for the profit it is expected to make: 9.2× its forward earnings, against 15.7×.
- HIK.L
Which pays more in dividends?
Hikma Pharmaceuticals pays more back in dividends for what a share costs: 3.84% a year, against 2.25%.
Which do analysts rate higher?
Analysts rate both the same: Strong buy.
- CTEC.L
Which is in the stronger price trend?
Convatec Group's price is in the stronger trend: 17.9% above its 200-day average, against 5.8% above.
What each company does
CTEC.LConvatec Group
Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally.
Reports results on 23 February 2027
HIK.LHikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products.
Reports results on 25 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.